Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015, Article ID 384860, 10 pages
http://dx.doi.org/10.1155/2015/384860
Review Article

Involvement of the Androgen and Glucocorticoid Receptors in Bladder Cancer

1Center for Hypertension and Personalized Medicine, Department of Physiology & Pharmacology, University of Toledo College of Medicine, Toledo, OH 43614, USA
2Department of Urology, University of Toledo College of Medicine, Toledo, OH 43614, USA

Received 2 April 2015; Revised 25 July 2015; Accepted 27 July 2015

Academic Editor: Franco Veglio

Copyright © 2015 Lucien McBeth et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2015,” CA: A Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5–29, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. H. W. Herr, D. M. Schwalb, Z.-F. Zhang et al., “Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial,” Journal of Clinical Oncology, vol. 13, no. 6, pp. 1404–1408, 1995. View at Google Scholar · View at Scopus
  3. K. D. Sievert, B. Amend, U. Nagele et al., “Economic aspects of bladder cancer: what are the benefits and costs?” World Journal of Urology, vol. 27, no. 3, pp. 295–300, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Chamie, M. S. Litwin, J. C. Bassett et al., “Recurrence of high-risk bladder cancer: a population-based analysis,” Cancer, vol. 119, no. 17, pp. 3219–3227, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Trikha, R. Corringham, B. Klein, and J.-F. Rossi, “Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence,” Clinical Cancer Research, vol. 9, no. 13, pp. 4653–4665, 2003. View at Google Scholar · View at Scopus
  6. M. Okamoto, K. Kawai, C. A. Reznikoff, and R. Oyasu, “Transformation in vitro of a nontumorigenic rat urothelial cell line by hydrogen peroxide,” Cancer Research, vol. 56, no. 20, pp. 4649–4653, 1996. View at Google Scholar · View at Scopus
  7. J. C. Webster, R. H. Oakley, C. M. Jewell, and J. A. Cidlowski, “Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative β isoform: a mechanism for the generation of glucocorticoid resistance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 12, pp. 6865–6870, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Ligr, Y. Li, S. K. Logan et al., “Mifepristone inhibits GRbeta coupled prostate cancer cell proliferation,” Journal of Urology, vol. 188, no. 3, pp. 981–988, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. A. W. Cheever, “Schistosomiasis and neoplasia,” Journal of the National Cancer Institute, vol. 61, no. 1, pp. 13–18, 1978. View at Google Scholar · View at Scopus
  10. J. D. Christie, D. Crouse, A. S. Kelada, E. Anis-Ishak, J. H. Smith, and I. A. Kamel, “Patterns of Schistosoma haematobium egg distribution in the human lower urinary tract. III. Cancerous lower urinary tracts,” The American Journal of Tropical Medicine and Hygiene, vol. 35, no. 4, pp. 759–764, 1986. View at Google Scholar · View at Scopus
  11. A. W. Cheever, R. E. Kuntz, J. A. Moore, and T.-C. Huang, “Pathology of Schistosoma haematobium infection in the capuchin monkey (Cebus apella),” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 82, no. 1, pp. 107–111, 1988. View at Publisher · View at Google Scholar · View at Scopus
  12. M. N. El-Bolkainy, N. M. Mokhtar, M. A. Ghoneim, and M. H. Hussein, “The impact of schistosomiasis on the pathology of bladder carcinoma,” Cancer, vol. 48, no. 12, pp. 2643–2648, 1981. View at Publisher · View at Google Scholar · View at Scopus
  13. H. M. Khaled, M. S. Aly, and I. T. Magrath, “Loss of Y chromosome in Bilharzial bladder cancer,” Cancer Genetics and Cytogenetics, vol. 117, no. 1, pp. 32–36, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. M. P. A. Zeegers, F. E. S. Tan, E. Dorant, and P. A. van den Brandt, “The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies,” Cancer, vol. 89, no. 3, pp. 630–639, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. S. H. Vermeulen, N. Hanum, A. J. Grotenhuis et al., “Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study,” British Journal of Cancer, vol. 112, no. 3, pp. 594–600, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. IARC Working Group, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 94 of Ingested Nitrate and Nitrite and Cyanobacterial Peptide Toxins, International Agency for Research on Cancer (IARC), Paris, France, 2010.
  17. P. Boffetta, N. Jourenkova, and P. Gustavsson, “Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons,” Cancer Causes and Control, vol. 8, no. 3, pp. 444–472, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. T. E. Arbuckle, “Are there sex and gender differences in acute exposure to chemicals in the same setting?” Environmental Research, vol. 101, no. 2, pp. 195–204, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. C. K. Batista, G. Brito, M. Souza, B. Leitão, F. Cunha, and R. Ribeiro, “A model of hemorrhagic cystitis induced with acrolein in mice,” Brazilian Journal of Medical and Biological Research, vol. 39, no. 11, pp. 1475–1481, 2006. View at Publisher · View at Google Scholar
  20. H. Kiuchi, T. Takao, K. Yamamoto et al., “Sesquiterpene lactone parthenolide ameliorates bladder inflammation and bladder overactivity in cyclophosphamide induced rat cystitis model by inhibiting nuclear factor-kappaB phosphorylation,” Journal of Urology, vol. 181, no. 5, pp. 2339–2348, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. B. F. Hales, S. Smith, and B. Robaire, “Cyclophosphamide in the seminal fluid of treated males: transmission to females by mating and effect on pregnancy outcome,” Toxicology and Applied Pharmacology, vol. 84, no. 3, pp. 423–430, 1986. View at Publisher · View at Google Scholar · View at Scopus
  22. J. M. Trasler, B. F. Hales, and B. Robaire, “Chronic low dose cyclophosphamide treatment of adult male rats: effect on fertility, pregnancy outcome and progeny,” Biology of Reproduction, vol. 34, no. 2, pp. 275–283, 1986. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Tubiana, “The report of the French Academy of Science: ‘problems associated with the effects of low doses of ionising radiation’,” Journal of Radiological Protection, vol. 18, no. 4, pp. 243–248, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. J. E. Trosko, “Role of low-level ionizing radiation in multi-step carcinogenic process,” Health Physics, vol. 70, no. 6, pp. 812–822, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Cardis, E. S. Gilbert, L. Carpenter et al., “Effects of low doses and low dose rates of external ionizing radiation: cancer mortality among nuclear industry workers in three countries,” Radiation Research, vol. 142, no. 2, pp. 117–132, 1995. View at Google Scholar
  26. J. D. Boice Jr., G. Engholm, R. A. Kleinerman et al., “Radiation dose and second cancer risk in patients treated for cancer of the cervix,” Radiation Research, vol. 116, no. 1, pp. 3–55, 1988. View at Publisher · View at Google Scholar
  27. A. Morales, D. Eidinger, and A. W. Bruce, “Intracavitary Bacillus Calmette Guerin in the treatment of superficial bladder tumors,” Journal of Urology, vol. 116, no. 2, pp. 180–183, 1976. View at Google Scholar · View at Scopus
  28. R. De Jager, E. Guinan, D. Lamm et al., “Long-term complete remission in bladder carcinoma in situ with intravesical tice bacillus Calmette guerin. Overview analysis of six phase II clinical trials,” Urology, vol. 38, no. 6, pp. 507–513, 1991. View at Publisher · View at Google Scholar · View at Scopus
  29. M. S. Cookson and M. F. Sarosdy, “Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy,” The Journal of Urology, vol. 148, no. 3, pp. 797–801, 1992. View at Google Scholar · View at Scopus
  30. R. Kapoor, V. Vijjan, and P. Singh, “Bacillus Calmette-Guerin in the management of superficial bladder cancer,” Indian Journal of Urology, vol. 24, no. 1, pp. 72–76, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Ikeda, I. Toida, A. Iwasaki, K. Kawai, and H. Akaza, “Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guérin (BCG): a role of BCG internalization into tumor cells,” International Journal of Urology, vol. 9, no. 1, pp. 29–35, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. J. A. Witjes, “Management of BCG failures in superficial bladder cancer: a review,” European Urology, vol. 49, no. 5, pp. 790–797, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Baniel, Z. Lev, D. Engelstein, and C. Servadio, “Penile edema and meatal ulceration after intravesical instillation with Bacillus Calmette-Guérin,” Urology, vol. 47, no. 6, pp. 932–934, 1996. View at Publisher · View at Google Scholar · View at Scopus
  34. V. Demers and V. Pelsser, “‘BCGitis’: a rare case of tuberculous epididymo-orchitis following intravesical bacillus Calmette-Guerin therapy,” Journal of Radiology Case Reports, vol. 6, no. 11, pp. 16–21, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Muttarak, B. Lojanapiwat, B. Chaiwun, and S. Wudhikarn, “Preoperative diagnosis of bilateral tuberculous epididymo-orchitis following intravesical Bacillus Calmette-Guerin therapy for superficial bladder carcinoma,” Australasian Radiology, vol. 46, no. 2, pp. 183–185, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Garg, S. N. Sankhwar, A. Goel et al., “Effect of intravesical immunotherapy on sperm parameters in young patients with non—muscle-invasive bladder carcinoma: prospective analysis,” Clinical Genitourinary Cancer, vol. 12, no. 3, pp. e83–e86, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. R. K. Naz and G. P. Talwar, “Immunological sterilization of male dogs by BCG,” International Journal of Andrology, vol. 4, no. 1, pp. 111–128, 1981. View at Google Scholar · View at Scopus
  38. S. Edin, M. L. Wikberg, A. M. Dahlin et al., “The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer,” PLoS ONE, vol. 7, no. 10, Article ID e47045, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. G. Gakis, “The role of inflammation in bladder cancer,” Advances in Experimental Medicine and Biology, vol. 816, pp. 183–196, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. Z. Zhu, Z. Shen, and C. Xu, “Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer,” Mediators of Inflammation, vol. 2012, Article ID 528690, 11 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Said, H. F. Frierson, M. Sanchez-Carbayo, R. A. Brekken, and D. Theodorescu, “Loss of SPARC in bladder cancer enhances carcinogenesis and progression,” The Journal of Clinical Investigation, vol. 123, no. 2, pp. 751–766, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Ajili, N. Kourda, A. Darouiche, M. Chebil, and S. Boubaker, “Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by bcg immunotherapy,” Ultrastructural Pathology, vol. 37, no. 1, pp. 56–61, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Dufresne, G. Dumas, É. Asselin, C. Carrier, M. Pouliot, and C. Reyes-Moreno, “Pro-inflammatory type-1 and anti-inflammatory type-2 macrophages differentially modulate cell survival and invasion of human bladder carcinoma T24 cells,” Molecular Immunology, vol. 48, no. 12-13, pp. 1556–1567, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Chen, W. Yong, T. D. Hinds Jr. et al., “Fkbp52 regulates androgen receptor transactivation activity and male urethra morphogenesis,” The Journal of Biological Chemistry, vol. 285, no. 36, pp. 27776–27784, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Enkelmann, J. Heinzelmann, F. Von Eggeling et al., “Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer,” Journal of Cancer Research and Clinical Oncology, vol. 137, no. 5, pp. 751–759, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. H. T. Niu, C. M. Yang, G. Jiang et al., “Cancer stroma proteome expression profile of superficial bladder transitional cell carcinoma and biomarker discovery,” Journal of Cancer Research and Clinical Oncology, vol. 137, no. 8, pp. 1273–1282, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. J. E. Castelao, J.-M. Yuan, M. Gago-Dominguez, M. C. Yu, and R. K. Ross, “Non-steroidal anti-inflammatory drugs and bladder cancer prevention,” British Journal of Cancer, vol. 82, no. 7, pp. 1364–1369, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. R. D. Klein, C. S. van Pelt, A. L. Sabichi et al., “Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression,” Cancer Research, vol. 65, no. 5, pp. 1808–1813, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. S. F. Shariat, J.-H. Kim, G. E. Ayala, K. Kho, T. M. Wheeler, and S. P. Lerner, “Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder,” Journal of Urology, vol. 169, no. 3, pp. 938–942, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. P. J. Boström, V. Aaltonen, K.-O. Söderström, P. Uotila, and M. Laato, “Expression of cyclooxygenase-1 and -2 in urinary bladder carcinomas in vivo and in vitro and prostaglandin E2 synthesis in cultured bladder cancer cells,” Pathology, vol. 33, no. 4, pp. 469–474, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. W. Lim, C. Park, M. K. Shim, Y. H. Lee, Y. M. Lee, and Y. Lee, “Glucocorticoids suppress hypoxia-induced COX-2 and hypoxia inducible factor-1α expression through the induction of glucocorticoid-induced leucine zipper,” British Journal of Pharmacology, vol. 171, no. 3, pp. 735–745, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. B. J. Deroo and T. K. Archer, “Glucocorticoid receptor activation of the I kappa B alpha promoter within chromatin,” Molecular Biology of the Cell, vol. 12, no. 11, pp. 3365–3374, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. G. P. Chrousos and T. Kino, “Intracellular glucocorticoid signaling: a formerly simple system turns stochastic,” Science's STKE, vol. 2005, no. 304, p. pe48, 2005. View at Google Scholar · View at Scopus
  54. L. J. Lewis-Tuffin and J. A. Cidlowski, “The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance,” Annals of the New York Academy of Sciences, vol. 1069, pp. 1–9, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. T. D. Hinds Jr., S. Ramakrishnan, H. A. Cash et al., “Discovery of glucocorticoid receptor-beta in mice with a role in metabolism,” Molecular Endocrinology, vol. 24, no. 9, pp. 1715–1727, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. L. A. Stechschulte, L. Wuescher, J. S. Marino, J. W. Hill, C. Eng, and T. D. Hinds Jr., “Glucocorticoid receptor beta stimulates Akt1 growth pathway by attenuation of pten,” The Journal of Biological Chemistry, vol. 289, no. 25, pp. 17885–17894, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. J. R. Tata, “Signalling through nuclear receptors,” Nature Reviews Molecular Cell Biology, vol. 3, no. 9, pp. 702–710, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. R. Kumar, B. H. Johnson, and E. B. Thompson, “Overview of the structural basis for transcription regulation by nuclear hormone receptors,” Essays in Biochemistry, vol. 40, pp. 27–39, 2004. View at Google Scholar · View at Scopus
  59. I. Rogatsky, J. M. Trowbridge, and M. J. Garabedian, “Glucocorticoid receptor-mediated cell cycle arrest is achieved through distinct cell-specific transcriptional regulatory mechanisms,” Molecular and Cellular Biology, vol. 17, no. 6, pp. 3181–3193, 1997. View at Google Scholar · View at Scopus
  60. A. Yemelyanov, J. Czwornog, D. Chebotaev et al., “Tumor suppressor activity of glucocorticoid receptor in the prostate,” Oncogene, vol. 26, no. 13, pp. 1885–1896, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. Z. Ni, J. Tang, Z. Cai et al., “A new pathway of glucocorticoid action for asthma treatment through the regulation of PTEN expression,” Respiratory Research, vol. 12, article 47, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. C. M. Bamberger, A.-M. Bamberger, M. De Castro, and G. P. Chrousos, “Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans,” The Journal of Clinical Investigation, vol. 95, no. 6, pp. 2435–2441, 1995. View at Publisher · View at Google Scholar · View at Scopus
  63. D. Y. M. Leung, Q. Hamid, A. Vottero et al., “Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor β,” Journal of Experimental Medicine, vol. 186, no. 9, pp. 1567–1574, 1997. View at Publisher · View at Google Scholar · View at Scopus
  64. R. H. Oakley, C. M. Jewell, M. R. Yudt, D. M. Bofetiado, and J. A. Cidlowski, “The dominant negative activity of the human glucocorticoid receptor β isoform. Specificity and mechanisms of action,” The Journal of Biological Chemistry, vol. 274, no. 39, pp. 27857–27866, 1999. View at Publisher · View at Google Scholar · View at Scopus
  65. Y. Yin, X. Zhang, Z. Li et al., “Glucocorticoid receptor β regulates injury-mediated astrocyte activation and contributes to glioma pathogenesis via modulation of β-catenin/TCF transcriptional activity,” Neurobiology of Disease, vol. 59, pp. 165–176, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. D. Y. M. Leung, M. De Castro, S. J. Szefler, and G. P. Chrousos, “Mechanisms of glucocorticoid-resistant asthma,” Annals of the New York Academy of Sciences, vol. 840, pp. 735–746, 1998. View at Publisher · View at Google Scholar · View at Scopus
  67. C. A. Longui, A. Vottero, P. Adamson et al., “Low glucocorticoid receptor alpha/beta ratio in T-cell lymphoblastic leukemia,” Hormone and Metabolic Research, vol. 32, no. 10, pp. 401–406, 2000. View at Publisher · View at Google Scholar
  68. X. Zhang, C. M. Ognibene, A. F. Clark, and T. Yorio, “Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta,” Experimental Eye Research, vol. 84, no. 2, pp. 275–284, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. Y. C. Zheng, K. Izumi, Y. Li, H. Ishiguro, and H. Miyamoto, “Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasone-mediated glucocorticoid receptor signals,” Molecular Cancer Therapeutics, vol. 11, no. 12, pp. 2621–2632, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. H. Ishiguro, T. Kawahara, Y. Zheng, G. J. Netto, and H. Miyamoto, “Reduced glucocorticoid receptor expression predicts bladder tumor recurrence and progression,” The American Journal of Clinical Pathology, vol. 142, no. 2, pp. 157–164, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. K. Dietrich, A. Schned, J. Fortuny et al., “Glucocorticoid therapy and risk of bladder cancer,” British Journal of Cancer, vol. 101, no. 8, pp. 1316–1320, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. Y. Zheng, K. Izumi, Y. Li, H. Ishiguro, and H. Miyamoto, “Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasone-mediated glucocorticoid receptor signals,” Molecular Cancer Therapeutics, vol. 11, no. 12, pp. 2621–2632, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. H. Ishiguro, T. Kawahara, Y. Zheng, E. Kashiwagi, Y. Li, and H. Miyamoto, “Differential regulation of bladder cancer growth by various glucocorticoids: corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity,” Cancer Chemotherapy and Pharmacology, vol. 74, no. 2, pp. 249–255, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. N. A. T. M. Huizenga, P. De Lange, J. W. Koper et al., “Five patients with biochemical and/or clinical generalized glucocorticoid resistance without alterations in the glucocorticoid receptor gene,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 5, pp. 2076–2081, 2000. View at Publisher · View at Google Scholar · View at Scopus
  75. G. Schlossmacher, A. Stevens, and A. White, “Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells,” Journal of Endocrinology, vol. 211, no. 1, pp. 17–25, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. C. Zhang, J. Mattern, A. Haferkamp et al., “Corticosteroid-induced chemotherapy resistance in urological cancers,” Cancer Biology and Therapy, vol. 5, no. 1, pp. 59–64, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. Y. Niu, S. Altuwaijri, S. Yeh et al., “Targeting the stromal androgen receptor in primary prostate tumors at earlier stages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 34, pp. 12188–12193, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. G. Gakis, A. Stenzl, and M. Renninger, “Evolution of the concept of androgen-sensitive bladder cancer,” Scandinavian Journal of Urology, vol. 47, no. 3, pp. 173–178, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. I. Lucca, H. Fajkovic, and T. Klatte, “Sex steroids and gender differences in nonmuscle invasive bladder cancer,” Current Opinion in Urology, vol. 24, no. 5, pp. 500–505, 2014. View at Publisher · View at Google Scholar · View at Scopus
  80. C. A. Heinlein and C. Chang, “Androgen receptor in prostate cancer,” Endocrine Reviews, vol. 25, no. 2, pp. 276–308, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. H. Miyamoto, E. M. Messing, and C. Chang, “Androgen deprivation therapy for prostate cancer: current status and future prospects,” Prostate, vol. 61, no. 4, pp. 332–353, 2004. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Rahman, H. Miyamoto, and C. Chang, “Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications,” Clinical Cancer Research, vol. 10, no. 7, pp. 2208–2219, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. S. Yeh, H.-C. Chang, H. Miyamoto et al., “Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators,” Keio Journal of Medicine, vol. 48, no. 2, pp. 87–92, 1999. View at Publisher · View at Google Scholar · View at Scopus
  84. J. D. Chen, “Steroid/nuclear receptor coactivators,” Vitamins and Hormones, vol. 58, pp. 391–448, 2000. View at Publisher · View at Google Scholar · View at Scopus
  85. F. Chen, P. Langenstroer, G. Zhang, Y. Iwamoto, and W. A. See, “Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines,” Journal of Urology, vol. 170, no. 5, pp. 2009–2013, 2003. View at Publisher · View at Google Scholar · View at Scopus
  86. H. Miyamoto, Z. Yang, Y.-T. Chen et al., “Promotion of bladder cancer development and progression by androgen receptor signals,” Journal of the National Cancer Institute, vol. 99, no. 7, pp. 558–568, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. A. M. Johnson, M. J. O'Connell, H. Miyamoto et al., “Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1,” BMC Urology, vol. 8, article 7, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. S. A. Boorjian, H. V. Heemers, I. Frank et al., “Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder,” Endocrine-Related Cancer, vol. 16, no. 1, pp. 123–137, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. E. C. Kauffman, B. D. Robinson, M. J. Downes et al., “Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer,” Molecular Carcinogenesis, vol. 50, no. 12, pp. 931–944, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. B. A. Rosenzweig, P. S. Bolina, L. Birch, C. Moran, I. Marcovici, and G. S. Prins, “Location and concentration of estrogen, progesterone, and androgen receptors in the bladder and urethra of the rabbit,” Neurourology and Urodynamics, vol. 14, no. 1, pp. 87–96, 1995. View at Publisher · View at Google Scholar · View at Scopus
  91. G. Pelletier, “Localization of androgen and estrogen receptors in rat and primate tissues,” Histology and Histopathology, vol. 15, no. 4, pp. 1261–1270, 2000. View at Google Scholar · View at Scopus
  92. C. M. Wilson and M. J. McPhaul, “A and B forms of the androgen receptor are expressed in a variety of human tissues,” Molecular and Cellular Endocrinology, vol. 120, no. 1, pp. 51–57, 1996. View at Publisher · View at Google Scholar · View at Scopus
  93. S. Salmi, R. Santti, J.-Å. Gustafsson, and S. Mäkelä, “Co-localization of androgen receptor with estrogen receptor beta in the lower urinary tract of the male rat,” Journal of Urology, vol. 166, no. 2, pp. 674–677, 2001. View at Publisher · View at Google Scholar · View at Scopus
  94. S. Celayir, Z. Ilçe, and S. Dervisoglu, “The sex hormone receptors in the bladder in childhood—I: preliminary report in male subjects,” European Journal of Pediatric Surgery, vol. 12, no. 5, pp. 312–317, 2002. View at Publisher · View at Google Scholar · View at Scopus
  95. H. J. Litman, S. Bhasin, M. P. O'Leary, C. L. Link, and J. B. McKinlay, “An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston Area Community Health survey,” BJU International, vol. 100, no. 2, pp. 321–326, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. Y. Zheng, K. Izumi, J. L. Yao, and H. Miyamoto, “Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells,” Endocrine-Related Cancer, vol. 18, no. 4, pp. 451–464, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. L. Cheng, G. T. MacLennan, C. X. Pan et al., “Allelic loss of the active X chromosome during bladder carcinogenesis,” Archives of Pathology & Laboratory Medicine, vol. 128, no. 2, pp. 187–190, 2004. View at Google Scholar
  98. L. M. Reid, I. Leav, and P. W. L. Kwan, “Characterization of a human, sex steroid-responsive transitional cell carcinoma maintained as a tumor line (R 198) in athymic nude mice,” Cancer Research, vol. 44, no. 10, pp. 4560–4573, 1984. View at Google Scholar · View at Scopus
  99. J.-W. Hsu, I. Hsu, D. Xu et al., “Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor,” American Journal of Pathology, vol. 182, no. 5, pp. 1811–1820, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. S. Boorjian, S. Ugras, N. P. Mongan et al., “Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer,” Urology, vol. 64, no. 2, pp. 383–388, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. W. Tan, S. Boorjian, P. Advani et al., “The estrogen pathway: estrogen receptor-α, progesterone receptor, and estrogen receptor-β expression in radical cystectomy urothelial cell carcinoma specimens,” Clinical Genitourinary Cancer, 2015. View at Publisher · View at Google Scholar
  102. S. S. Shen, C. L. Smith, J.-T. Hsieh et al., “Expression of estrogen receptors-α and -β in bladder cancer cell lines and human bladder tumor tissue,” Cancer, vol. 106, no. 12, pp. 2610–2616, 2006. View at Publisher · View at Google Scholar · View at Scopus
  103. H. T. Kim, B. C. Kim, I. Y. Kim et al., “Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis through cleavage of BAD in TSU-PR1 human cancer cells,” The Journal of Biological Chemistry, vol. 277, no. 36, pp. 32510–32515, 2002. View at Publisher · View at Google Scholar · View at Scopus
  104. S. Karmakar, Y. Jin, and A. K. Nagaich, “Interaction of glucocorticoid receptor (GR) with estrogen receptor (ER) alpha and activator protein 1 (AP1) in dexamethasone-mediated interference of ERalpha activity,” The Journal of Biological Chemistry, vol. 288, no. 33, pp. 24020–24034, 2013. View at Publisher · View at Google Scholar · View at Scopus
  105. M.-J. Tsai and B. W. O'Malley, “Molecular mechanisms of action of steroid/thyroid receptor superfamily members,” Annual Review of Biochemistry, vol. 63, pp. 451–486, 1994. View at Publisher · View at Google Scholar · View at Scopus
  106. A. O. Brinkmann and J. Trapman, “Prostate cancer schemes for androgen escape,” Nature Medicine, vol. 6, no. 6, pp. 628–629, 2000. View at Publisher · View at Google Scholar · View at Scopus
  107. A. O. Brinkmann, “Molecular basis of androgen insensitivity,” Molecular and Cellular Endocrinology, vol. 179, no. 1-2, pp. 105–109, 2001. View at Publisher · View at Google Scholar · View at Scopus
  108. J. T. Isaacs and W. B. Isaacs, “Androgen receptor outwits prostate cancer drugs,” Nature Medicine, vol. 10, no. 1, pp. 26–27, 2004. View at Publisher · View at Google Scholar · View at Scopus
  109. G. N. Brooke and C. L. Bevan, “The role of androgen receptor mutations in prostate cancer progression,” Current Genomics, vol. 10, no. 1, pp. 18–25, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. P. Gupta, M. Jain, R. Kapoor, K. Muruganandham, A. Srivastava, and A. Mandhani, “Impact of age and gender on the clinicopathological characteristics of bladder cancer,” Indian Journal of Urology, vol. 25, no. 2, pp. 207–210, 2009. View at Publisher · View at Google Scholar · View at Scopus
  111. Y. Jing, D. Cui, W. Guo et al., “Activated androgen receptor promotes bladder cancer metastasis via Slug mediated epithelial-mesenchymal transition,” Cancer Letters, vol. 348, no. 1-2, pp. 135–145, 2014. View at Publisher · View at Google Scholar · View at Scopus
  112. W. Jitao, H. Jinchen, L. Qingzuo et al., “Androgen receptor inducing bladder cancer progression by promoting an epithelial-mesenchymal transition,” Andrologia, vol. 46, no. 10, pp. 1128–1133, 2014. View at Publisher · View at Google Scholar · View at Scopus
  113. N. Ferrara, K. Carver-Moore, H. Chen et al., “Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene,” Nature, vol. 380, no. 6573, pp. 439–442, 1996. View at Publisher · View at Google Scholar · View at Scopus
  114. D. R. Bielenberg, C. A. Pettaway, S. Takashima, and M. Klagsbrun, “Neuropilins in neoplasms: expression, regulation, and function,” Experimental Cell Research, vol. 312, no. 5, pp. 584–593, 2006. View at Publisher · View at Google Scholar · View at Scopus
  115. J. R. L. Wild, C. A. Staton, K. Chapple, and B. M. Corfe, “Neuropilins: expression and roles in the epithelium,” International Journal of Experimental Pathology, vol. 93, no. 2, pp. 81–103, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. A. M. Jubb, L. A. Strickland, S. D. Liu, J. Mak, M. Schmidt, and H. Koeppen, “Neuropilin-1 expression in cancer and development,” Journal of Pathology, vol. 226, no. 1, pp. 50–60, 2012. View at Publisher · View at Google Scholar · View at Scopus
  117. A. M. Jubb, S. M. Sa, N. Ratti et al., “Neuropilin-2 expression in cancer,” Histopathology, vol. 61, no. 3, pp. 340–349, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. M. R. Saban, T. J. Sferra, C. A. Davis et al., “Neuropilin-VEGF signaling pathway acts as a key modulator of vascular, lymphatic, and inflammatory cell responses of the bladder to intravesical BCG treatment,” The American Journal of Physiology—Renal Physiology, vol. 299, no. 6, pp. F1245–F1256, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. W. D. Stamer, E. A. Hoffman, J. M. Luther, D. L. Hachey, and K. L. Schey, “Protein profile of exosomes from trabecular meshwork cells,” Journal of Proteomics, vol. 74, no. 6, pp. 796–804, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. P. Mirabelli, B. B. Peebo, M. Xeroudaki, M. Koulikovska, and N. Lagali, “Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularization model,” Experimental Eye Research, vol. 125, pp. 118–127, 2014. View at Publisher · View at Google Scholar · View at Scopus
  121. K. Eisermann, C. J. Broderick, A. Bazarov, M. M. Moazam, and G. C. Fraizer, “Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site,” Molecular Cancer, vol. 12, article 7, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. A. Gericke, M. Munson, and A. H. Ross, “Regulation of the PTEN phosphatase,” Gene, vol. 374, no. 1-2, pp. 1–9, 2006. View at Publisher · View at Google Scholar · View at Scopus